NEW YORK – Scandinavian private equity firm Summa Equity said Wednesday that it has acquired functional proteomics firm Sengenics.
Founded in 2008, Sengenics produces full-length folded protein arrays using its KREX protein folding technology. Currently, the company is focused on using the technology to discover autoantibody signatures that could be useful for detecting and managing autoimmune and infectious diseases and cancer.
The company also recently launched a COVID-19 serology test based on its technology that it is marketing for use in vaccine and population health research.
"Sengenics' proprietary technology unlocks tremendous potential for researchers around the world to further their understanding of biology and disease," Tommi Unkuri, partner at Summa Equity, said in a statement. "We look forward to supporting the Sengenics team in our shared ambition to invest to drive product development, global expansion, and accelerated adoption."
"We are excited to welcome Summa Equity as a major strategic investor and shareholder in Sengenics," said Sengenics CEO Arif Anwar in a statement. "Their extensive capabilities and alignment with our vision of changing the future of medicine through immune-proteomics is a very strong strategic fit."
Anwar added that Summa's ownership of Olink Proteomics gives it relevant expertise into Sengenics' business. Summa acquired Olink in 2019.